The Generics Bulletin Podcast: Teva, Sandoz, Sawai and US Orange Book patents

episode

Citeline Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Bringing Kashmir’s lakes back to life 25 min · 23 Sep 2026 · The Documentary Podcast

Soup 56 min · 23 Sep 2026 · Three Bean Salad

AFL Record Editor Ash Browne | Grand Final edition on sale now! (23.09.26) 2 min · 23 Sep 2026 · Whateley

NPR News: 09-22-2026 8PM EDT 4 min · 23 Sep 2026 · NPR News Now

Send Me To Sleep | Aristotle 44 min · 23 Sep 2026 · Send Me To Sleep

Finding the balance between offence & defence | The Art of Coaching with Ken Hinkley! (23.09.26) 5 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded07 Jun 2024

Publisherfeeds.soundcloud.com ↗

Handlerec:4677793

Show notes

Generics Bulletin's editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA's Orange Book.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related